Slingshot Biosciences

EMERYVILLE, CA · CIK 0001867067 · Biotech

slingshot.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$24M
2 Form D · Feb 2023
44 months since last filing
Contracts
—
No federal contracts on record
Patents
40
25 granted · 15 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$12,379,974
Private capital raisedForm D · SEC$11,227,334
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2069Isomorphic Labs——
2070Courier Therapeutics Inc——
2071UNLOCKED LABS INC.——
2072Slingshot Biosciences—$24M
2073ANI Energy, LLC—$1.5M
2074Key Health Institute of Edmond, LLC—$100K
2075RGENIX, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Nicolas BarthelemyDirector
  • Jeffrey KimDirector · Executive Officer
  • Andrew LeeDirector
  • Corey RitterDirector
  • Ronald SilbermanDirector
  • Patrick WeissDirector
  • Adam WieschhausDirector

Patents

USPTO · 25 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.